Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.